Sensars develops high-selective nerve stimulators and related neuromodulation technology, centering development on its SENSY product. The company advanced SENSY after securing EUR 1.1 million in funding from HTH, a VC focused on human health. Sensars is also leading the Eurostars SENSOLE project, a system that fuses wearable sensors, a neurostimulator and AI software to monitor and treat gait disabilities, backed by a EUR 500,000 grant. Sensars Germany received a EUR 600,000 grant from the BMBF to test SENSY in amputees in collaboration with the University of Heidelberg. The firm's approach emphasizes producing natural touch and movement sensations to improve pain management compared with conventional stimulators. Sensars has received startup recognition including Venture Kick, participation in Venture Leaders Life Sciences, and inclusion in the TOP 100 Swiss Startups in 2017; Francesco Petrini is co-founder and CEO.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2024